Last Updated : August 22, 2023
Details
Generic Name:
infliximab
Project Status:
Pending
Therapeutic Area:
Crohn’s disease and Ulcerative Colitis
Manufacturer:
Celltrion Healthcare Co., Ltd.
Call for patient/clinician input open:
Brand Name:
Remsima
Project Line:
Reimbursement Review
Project Number:
SR0816-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Reduction of signs and symptoms and maintenance of clinical remission and mucosal healing and reduction of corticosteroid use in adult patients with moderately to severely active Crohn’s disease who have had an inadequate response to a corticosteroid and/or aminosalicylate. REMSIMA™ SC can be used alone or in combination with conventional therapy. Reduction of signs and symptoms and maintenance of clinical remission and mucosal healing, and reduction or elimination of corticosteroid use in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy (i.e., aminosalicylate and/or corticosteroid and/or an immunosuppressant).
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Reduction of signs and symptoms and maintenance of clinical remission and mucosal healing and reduction of corticosteroid use in adult patients with moderately to severely active Crohn’s disease who have had an inadequate response to a corticosteroid and/or aminosalicylate. REMSIMA™ SC can be used alone or in combination with conventional therapy. Reduction of signs and symptoms and maintenance of clinical remission and mucosal healing, and reduction or elimination of corticosteroid use in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response ...
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Last Updated : August 22, 2023